Agency IQ

AUGUST 2, 2024

What We Expect the FDA to do in August and September 2024 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 40

FDA Science Regulations Biosimilars 40

The Pharma Data

MAY 15, 2023

Huebscher , non-executive board member in companies, institutions and former CEO of Solvias Group, a Swiss contract research firm, which she led between 2014 and 2021. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.

Science 40

Science Doctors Government Compliance 40

The Pharma Data

JULY 8, 2021

Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). These genetic data have been paired with detailed health information to create this browsable resource.

Disease 52

Disease Government Clinical Trials Research 52

The Pharma Data

DECEMBER 21, 2020

executive vice president of Research and Development at Amgen. We lead with science through discovery research that is disease-agnostic and biology-first, modality-second. Respir Med 2006 : 100 (7): 1139-51. Reese , M.D., In doing so, we have introduced and evolved novel therapies that have changed the lives of patients.

Trials 40

Trials Production Clinical Trials Government 40

Agency IQ

JULY 28, 2023

A big legislative question about PAHPA Reauthorization : The Pandemic and All-Hazards Preparedness Act (PAHPA) was originally passed in 2006. October 1, 2023 [link] Regulations Expected to be Published in Q3These are taken from the most recent version of the White House’s Unified Agenda.

FDA 40

FDA Science Biosimilars Regulations 40